Columbia University - Pediatric Cardiology, 3959 Broadway BH-2, North New York, New York 10032, USA.
Expert Opin Pharmacother. 2010 Jan;11(1):127-32. doi: 10.1517/14656560903413542.
Tadalafil, a long-acting phosphodiesterase-5 inhibitor (PDE-5) is the most recent oral agent to receive FDA approval for the treatment of pulmonary arterial hypertension (PAH).
With several new agents emerging for the treatment of PAH, this article reviews tadalafil, the compound and its properties, clinical evidence supporting its use, and the role of tadalafil in the current treatment approach for patients with PAH.
A broad PubMed literature search was performed to identify the most current data on the use of tadalafil for PAH.
Tadalafil received FDA approval in 2009 following the recently published pivotal trial that demonstrated that the use of tadalafil 40 mg once daily was well tolerated, improved exercise capacity and quality of life measures and reduced time to clinical worsening in PAH patients. As the second PDE-5 inhibitor to gain approval for PAH, clinical properties such as its long half-life leading to once-daily dosing and possibly improved compliance, as well as potential cost benefit, may distinguish tadalafil from sildenafil in the widespread treatment of PAH.
他达拉非是一种长效磷酸二酯酶-5 抑制剂（PDE-5），是最近获得美国食品药品监督管理局（FDA）批准用于治疗肺动脉高压（PAH）的口服药物。
随着几种新的治疗 PAH 的药物的出现，本文回顾了他达拉非这种化合物及其特性、支持其应用的临床证据，以及他达拉非在目前 PAH 患者治疗方法中的作用。
广泛检索 PubMed 文献，以确定关于他达拉非治疗 PAH 的最新数据。
在最近公布的一项关键性试验表明，每日一次使用他达拉非 40mg 可耐受良好，改善了运动能力和生活质量指标，并降低了 PAH 患者临床恶化的时间后，他达拉非于 2009 年获得 FDA 批准。作为第二个获得 PAH 批准的 PDE-5 抑制剂，他达拉非的临床特性，如半衰期长，可每日一次给药，可能提高了依从性，以及潜在的成本效益，可能使他达拉非与西地那非在广泛的 PAH 治疗中有所区别。
